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Delayed DNA double-strand break repair
following platin-based chemotherapy
predicts treatment response in head and
neck squamous cell carcinoma
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Introduction: The aim of this study was to investigate if defective repair of DNA double-strand break (DSB) in head and neck
squamous cell carcinoma (HNSCC) could be used as an early predictor of treatment response.
Methods: Tumour biopsy 24–36 h following induction chemotherapy (IC) and pre-treatment biopsies were stained for RAD51 and
geminin (S-phase marker) for immunofluorescence in patients with HNSCC. The difference between RAD51 score (percentage of
geminin-positive cells that were also positive for RAD51) was calculated for the two specimens. Tumours with a percentage
difference ofp10% were deemed to have repaired IC-induced DSBs, and were classified as ‘RAD51 negative’. Response at 3
months post treatment and human papilloma virus (HPV) status were assessed.
Results: Thirteen pairs of samples were available for analyses. Three samples were classified as RAD51 negative and 10 as RAD51
positive at 24 h post IC. All of the three patients with tumours classified as RAD51 negative had partial response or progressive
disease and the 10 patients with tumours deemed RAD51 positive had a complete response. 100% of the HPV-positive tumours
were RAD51 positive and had a complete response.
Conclusions: We have demonstrated that impaired DSB DNA repair may underlie enhanced treatment sensitivity of HPV-positive
HNSCC and repair capacity following platinum-induced DNA damage predicts response in HNSCC. This has potential as a
biomarker for patient selection in trials of DNA damage response pathway modulation.
Radiotherapy with concomitant chemotherapy (CRT) is a standard-
of-care for the non-surgical management of head and neck
squamous cell carcinoma (HNSCC). Unrepaired DNA double-
strand breaks (DSB) are the principal lesions that determine
responses in tumours and normal tissues, following treatment with
radiation and/or several cytotoxic agents (Willers et al, 2004). Error-
free DSB repair is done via homologous recombination (HR) using
sister chromatid DNA as a template (Jackson and Bartek, 2009). The
protein RAD51 is a key component of HR and forms foci at the
site of DSBs that can be visualised using immunofluorescence
(Graeser et al, 2010). HR forms one component of a complex
network of DNA damage response (DDR) pathways, functional
assessment of which in tumours might predict treatment sensitivity
or resistance (Willers et al, 2015).
Two studies in breast cancer have proven that RAD51 foci, as
seen on immunofluorescence in tumour biopsies taken after
*Correspondence: Dr SA Bhide; E-mail: shreerang.bhide@icr.ac.uk
Received 16 March 2016; revised 27 July 2016; accepted 1 August 2016; published online 1 September 2016
& 2016 Cancer Research UK. All rights reserved 0007 – 0920/16
SHORT COMMUNICATION
Keywords: deficient DNA DSB repair; treatment response; HNSCC; HPV positive
British Journal of Cancer (2016) 115, 825–830 | doi: 10.1038/bjc.2016.266
www.bjcancer.com |DOI:10.1038/bjc.2016.266 825
induction of DNA damage, can be used as a functional marker of
DDR (Graeser et al, 2010; Naipal et al, 2014). In addition, Graeser
et al demonstrated that delayed HR as determined by non-
resolution of RAD51 foci predict for response to neo-adjuvant
chemotherapy in patients with breast cancer. To our knowledge,
there have been no similar clinical studies in HNSCC. The aim of
this study was to investigate if delayed HR-mediated repair of
DNA DSB can be used as a predictive biomarker of response to
CRT in HNSCC.
MATERIALS AND METHODS
Eligible patients had stage III/IV SCC of the oropharynx, with
primary tumours that were visible trans-orally. All patients were
scheduled to receive IC followed by CRT according to a standard
regimen that has been previously described (Bhide et al, 2007;
Wilkins et al, 2013). Informed consent was obtained from all
subjects and the relevant research and development and ethics
committees approved the study.
Data on stage (AJCC 2007), smoking and human papilloma
virus (HPV) status (p16 immunohistochemistry (IHC)) and
response at 3 months post treatment were collected. Response at
3 months after treatment was assessed using PET-CT scans.
Residual disease as diagnosed on PET-CT scans was biopsy
confirmed. HPV status was confirmed using PCR with reverse
transcription (RT–PCR) for E6 mRNA in the diagnostic biopsy
(Smeets et al, 2007).
Study intervention. All patients underwent a punch biopsy of the
primary tumour under local anaesthetic between 24–30 h after
administration of platinum during the first cycle of IC. The biopsy
specimen was immediately fixed in a 10% neutral buffered
formalin solution (Sigma-Aldrich, St Louis, MO, USA) and
transferred to the pathology department at our institution for
preparation of formalin-fixed paraffin-embedded (FFPE) tumour
blocks. Haematoxylin-eosin stained slides prepared from the FFPE
material were reviewed by a consultant pathologist (KT) to confirm
the presence of tumour. Directly contiguous slides were cut for the
RAD51 and phosphorylated H2AX (gH2AX) analyses. gH2AX
staining was performed to confirm that the biopsied tumours had
been exposed to chemotherapy in concentrations sufficient to
induce DNA damage.
Pre-treatment FFPE tumour blocks, that were used for primary
diagnosis and hence had presence of tumour confirmed by a
specialist head and neck pathologist at relevant institution were
also obtained.
RAD51 immunofluorescence assay. The pre-treatment and post-
IC tumour blocks were stained using identical procotols previously
validated at our institution (Graeser et al, 2010). Irradiated FFPE
mouse xenograft was used as a positive control. Immunofluores-
cence analysis was carried out on 3 mm sections of FFPE tumour
material. Following antigen retrieval by microwaving at pH 9
(DAKO pH 9 buffer) for 18min, followed by 20min cooling in
buffer, sections were treated with Triton 0.2% for permeabilization
for 20min, washed in phosphate-buffered saline (PBS), treated
with 100 ml of DNAse I (Roche) 1 : 10 000 for 1 h at 37 1C and
blocked with immunofluorescence buffer (IFF; 1% bovine
serum albumin, 2% fetal bovine serum; PAA gold in PBS) for
30min at room temperature. Sections were stained with geminin
antibody (10802-1-AP, ProteinTech Group). 1 : 400 in IFF for 1 h
at room temperature, washed with PBS, followed by anti-rabbit
Alexa488 (Invitrogen, #A21121) conjugate 1 : 1000 in IFF for 1 h
at room temperature, washed with PBS, fixed with 4%
paraformaldehyde (PFA) solution for 15min, stained with
RAD51 antibody (Clone 14B4; GeneTex) 1 : 100 in IFF for 1 h
at room temperature, washed with PBS, followed by anti-mouse
Alexa555 conjugate (Invitrogen, #A21429) 1 : 1000 in IFF for 1 h
at room temperature, washed in PBS with 4’, 6 diamidino 2
phenylindole (DAPI; 1 : 10000) for 15min, and sections were
fixed again with 4% paraformaldehyde (Sigma-Aldrich). The
protocol for gH2AX staining was similar, with primary antibody
1 : 500 (phospho- Histone H2AX Ser139 Clone JBW301; Millipore)
in IFF for 1 h at RT.
Scoring RAD51 foci. Images were captured on a Leica TCS
confocal microscope (Leica Microsystems, Milton Keynes, Bucks,
UK) set up with the laser outputs controlled via the Acousto-
Optical Tunable Filter and the four collection windows using the
Acousto-Optical Beam Splitter as follows; 403 nm laser (25%)
window 410–483 nm, 488 nm laser (25%) window 493–538 nm,
543 nm laser (100%) window 548–628 nm and 633 nm laser (25%)
window 638–700 nm. Images were collected using the microscope
in sequential mode with a line average of 4 and a format of
1024ÅB1024 pixels. The image acquisition protocol for the study
samples was calibrated based on the positive control. Three
investigators blinded to the time-point of the sample and all
clinical data, including clinical response, counted the foci
independently. The staining of nuclear foci was scored as follows.
Between 100 and 500 cells in the sub-epithelial layer (invasive
tumour) with any nuclear geminin staining (S-phase marker), were
counted at representative areas across the section. A cell with any
nuclear geminin staining was counted as being positive and in
S-phase of the cell cycle. Any geminin positive cell in the
sub-epithelial layer would be a proliferating cell and by definition
a tumour cell. RAD51 foci were only counted in the geminin-
positive cells. A cell was counted as being RAD51 positive if there
was at least one distinct focus per nucleus. gH2AX staining was
performed on a contiguous section, with a cell at least one focus
considered positive. This threshold was selected as per the
previous study by Graeser et al (2010). The mean of the foci
counted by the three independent investigators was calculated.
The percentage of geminin-positive cells that were also positive
for RAD51 was calculated as the RAD51 score for pre-treatment
and 24 h post-treatment specimens. The difference between the
RAD51 score for the two specimens was then calculated. Tumour
specimens with a percentage difference of p10% between
pre- and post-treatment specimens were deemed to have repaired
the IC-induced DSBs, and were classified as RAD51 negative. The
remaining patients were classified as RAD51 positive. This limit
was set, as per Graeser et al (2010), before unblinding the
response data.
RESULTS
Fifteen patients were recruited into the study. The pre-treatment
diagnostic biopsy was unavailable for one patient and geminin
immunofluorescence staining was deemed to be of insufficient
quality in one post-IC biopsy sample. Therefore, 13 pairs of
samples were available for detailed analysis. Table 1 details the
demographic data for these patients. IHC and RT–PCR were in
agreement and confirmed that five tumours were HPV-negative
and eight were HPV-positive.
The median RAD51 scores for the pre- and post-IC samples
were 12 and 50%, respectively. Based on a cut-off of persistence of
RAD51 foci atoor 410% above baseline, three tumours were
classified as RAD51 negative (o10%) and ten as RAD51 positive
(410%) at 24-hours post-IC. Figure 1 shows example confocal
images for RAD51 negative (1A) and RAD51 positive (1B)
tumours. Pre- and post-IC samples demonstrated 20% average
increase in percentage of gH2AX foci (Supplementary Figure 1).
There was no difference in the tumours samples from RAD51
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negative (58% increase) and positive (52% increase) patients
(Supplementary Figures 2 and 3).
Treatment outcomes at 3 months post CRT are detailed in
Table 1. Complete clinical and radiological responses (CR) to CRT
at this time were achieved for 10/13 (77%) patients; the remaining
3/13 (23%) patients had evidence of persistent or progressive
disease (PD). All of the three patients classified as having RAD51-
negative tumours had persistent or PD and the 10 patients with
RAD51-positive tumours had a CR (Table 1 and Figure 2). Two
out of the five (40%) patients with HPV-negative disease and 100%
Table 1. Clinical characteristics, RAD 51 status and treatment response of patients
Trial no. Stage HPV status
Smoking status
(pack years) Prognostic group
Difference in RAD51 foci
pre- and post-IC (%) RAD 51 status
Treatment
response
1002 T2N2B  ve 30 Poor 31 Positive CR
1003 T4N2B þ ve 20 Intermediate 25 Positive CR
1004 T4N2B  ve 40 Poor 7 Negative PR
1005 T2N2B  ve 20 Poor 3 Negative PR
1006 T2N2B þ ve Never Good 62 Positive CR
1007 T2N1 þ ve Never Good 44 Positive CR
1008 T3N2B þ ve 30 Intermediate 71 Positive CR
1009 T3N0 þ ve 15 Good 74 Positive CR
1010 T4N2C þ ve 30 Intermediate 27 Positive CR
1011 T3N2B þ ve 30 Intermediate 72 Positive CR
1013 T4N2B  ve 40 Poor 3 Negative PR
1014 T2N2B  ve 40 Poor 27 Positive CR
1015 T3N2B þ ve Never Good 57 Positive CR
Abbreviations: CR¼ complete response; HPV¼ human papilloma virus; PR¼partial response.
1
2
3
4
Pre-IC Pre-ICPost-IC Post-ICA B
Figure 1. Shows typical example of confocal images with immunofluorescence for DAPI (blue, 1), geminin (green, 2) RAD51 (red, 3) and
overlaid (4). (A) (RAD51-negative tumours) shows similar proportion of geminin positive with Rad51 foci in post-IC compared with pre-IC images
and (B) (RAD51-positive tumours) shows increased proportion of cells with RAD51 foci in post-IC images.
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of the patients with HPV-positive disease had RAD51-positive
tumours and had a CR. All three RAD51-negative tumours with
PD were HPV-negative and would have been predicted to be in the
poor prognosis group according to the Ang classification (Ang
et al, 2010).
DISCUSSION
This study demonstrates that HR functional status, as determined
by resolution of RAD51 foci following induction of DNA damage
by platinum-containing chemotherapy, predicts treatment
response after CRT for HNSCC.
We were able to classify the patients with HPV-negative tumours
into responders (40%) and non-responders (60%) based on the
repair of RAD51 foci of their tumours. There was no difference in
the gH2AX foci induction in RAD51-negative and -positive patients,
indicating that the differences in the RAD51 foci were as a result of
differences in tumour biology and opposed to poor chemotherapy
exposure. HNSCC can be divided into good, intermediate and poor
prognosis groups based on HPV status, tumour stage and smoking
history (Ang et al, 2010). Clinical trials of treatment de-escalation in
the good prognosis group (HPV-positive) are currently underway
(Masterson et al, 2014) and dose-intensification strategies are being
explored in the poor prognosis group (Dillon and Harrington,
2015). One approach to treatment intensification is through DDR
pathway modulation, based on the high prevalence of TP53
mutations and the resulting dysfunction in downstream DDR
pathways in HPV-negative HNSCC (Dillon et al, 2014). DNA DSB
repair status, as determined in this study, could potentially be used
as a biomarker to identify patients with RAD51 negative tumours
who might benefit from DDR modulation during CRT.
All of the HPV-positive tumours in this study were RAD51
positive and had CR following treatment. This suggests that
impaired DNA DSB repair might underlie significantly higher
response rates observed in HPV-positive HNSCC. Previous in vitro
studies have shown that impaired DNA DSB repair might underlie
enhanced treatment sensitivity in HPV-positive HNSCC
(Rieckmann et al, 2013; Park et al, 2014). Ours is the first study
to provide clinical proof-of-principle for this hypothesis by
assessing DSB repair in tumour biopsies before and after DNA-
damaging therapy.
Previous IHC-based studies have correlated RAD51 expression
to outcomes in HNSCC (Connell et al, 2006). However, HR
protein expression at a single time-point does not provide
information on the HR function DSB repair following DNA
damage. This can be considered to be a major drawback when
considering this as a predictive biomarker for treatment persona-
lisation. The study by Graeser et al (2010) is the only other study
that assessed DSB repair following induction of DNA damage,
albeit in patients with breast cancer.
The Fanconi Anaemia pathway status for tumour samples was
not known. The Fanconi Anaemia pathway consists of a network
of up to 15 proteins, encoded by different genes (Thompson and
Hinz, 2009). These proteins control DNA replication and
mutagenic responses to endogenous and exogenous DNA damage.
The functional status of this pathway can be affected by altered
gene expression either through mutations or altered methylation
status. Therefore, the complete characterisation of Fanconi
Anaemia pathway status would have required assessment of the
mutational and methylation status of all of the pathway genes.
Unfortunately adequate tumour material was not available to
undertake such an analyses. Not knowing the Fanconi Anaemia
pathway status in these tumours can be considered a drawback of
this study, nevertheless, somatic mutations in this pathway are
highly uncommon in HPV-positive and HPV-negative head and
neck SCC (Agrawal et al, 2011; Stransky et al, 2011).
This was a pilot study with a small sample size. Therefore formal
statistical tests for comparisons were not undertaken. However, we
have used validated scientific methodology with adequate controls
and have accounted for cell cycle (S) phase dependence of the DSB
repair pathway using geminin staining. DNA damage was induced
in this study by platinum-containing IC. However, the use of IC in
clinical practice continues to decline, in light of evidence of
only marginal benefits when compared with CRT alone
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(Pignon et al, 2009; O’Sullivan et al, 2013). Therefore, it will be
important to repeat this study on tumour samples taken
before and after CRT. However, larger studies are required to
validate our current findings and this is likely to be challenging
given the invasive nature of repeated biopsies (especially during
treatment). Preliminary studies have demonstrated the potential
utility of analysing HR function in microRNA and circulating
tumour DNA samples obtained at venesection. Such samples
could be used for larger validation studies (Nel et al, 2013;
Liu et al, 2015).
CONCLUSION
We have demonstrated that the failure to resolve RAD51 foci
following platin-induced DNA damage can be used as an index of
DSB repair and can predict response following CRT for HNSCC.
This assay holds promise as a potential biomarker for patient
selection in trials of DDR pathway modulation. In addition, this
study provides direct clinical evidence that delayed DSB repair may
explain the enhanced treatment sensitivity of HPV-positive
HNSCC.
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